Catalog No.
Product Name
Application
Product Information
Citations
- Fisetin is a flavonol, a structurally distinct chemical substance that belongs to the flavonoid group of polyphenols. It can be found in many plants, where it serves as a colouring agent. Possible anti-aging, anti-inflammatory, anti-cancer, and anti-viral properties of fisetin are under active scientific investigation.
- Bih-Cheng Chen, .et al. , Phytomedicine, 2019, Apr; 57:1-8 PMID: 30668312
- Jeng LB, .et al. , J Cell Physiol, 2018, Sep;233(9):7134-7142 PMID: 29574877
- Kuan-Ho Lin, .et al. , Journal of Functional Foods, 2018, 52: 212-218
-
SIRT1 Activator
SRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.- Eleni Pitsillou, .et al. , Comput Biol Chem, 2020, 89: 107408 PMID: 33137690
- Jie Ren, .et al. , Sleep Breath, 2018, Nov 8 PMID: 30411173
- Rowlands BD, .et al. , J Neurochem, 2017, Mar;140(6):903-918 PMID: 27925207
- Adam Khader, .et al. , J Surg Res, 2017, Nov;219:288-295 PMID: 29078895
- Adam Khader, .et al. , Crit Care Med, 2016, Aug; 44(8): e651-e663 PMID: 26963320
- Benjamin D. Rowlands, .et al. , J Neurosci Res., 2015, Jul;93(7):1147-56 PMID: 25677687
- Khader A, .et al. , Transplantation, 2014, 98(2):148-56 PMID: 24918615
-
SIRT1 activator
SRT2104 (GSK2245840) is a selective SIRT1 activator involved in the regulation of energy homeostasis. Phase 2.- Eleni Pitsillou, .et al. , Comput Biol Chem, 2020, 89: 107408 PMID: 33137690
- Liu X, .et al. , Life Sci, 2019, Nov 9:117041 PMID: 31715188
-
p53 activator
Tenovin-6 is a analog of tenovin-1. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 in vitro with IC50 values of 21, 10, and 67 uM, respectively.- Igase M,, .et al. , Exp Cell Res, 2019, Dec 28:111810 PMID: 31891684
-
SIRT1 Activator
SRT 1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5 = 37 uM; SIRT3: EC1.5 > 300 uM).- Lanlan Yin, .et al. , Placenta, 2024, May:150:52-61 PMID: 38593636
-
SIRT1 inhibitor
EX 527 is a potent and selective SIRT1 class III histone deacetylase enzyme inhibitor with IC50 of 38 nM in a cell-free assay.- Lisha Zhao, .et al. , Sci Rep, 2025, May 28;15(1):18761 PMID: 40437103
- Yue He, .et al. , FASEB J, 2024, Oct 15;38(19):e70095 PMID: 39373984
- Qiang Chen, .et al. , J Bioenerg Biomembr, 2022, Feb;55(1):33-42 PMID: 36525212
- Flavien Bizot, .et al. , Mol Ther Nucleic Acids, 2022, Nov 21;30:606-620 PMID: 36514350
- Takeshi Nakamura, .et al. , Shimane Journal of Medical Science, 2022, 38 (2), 59-66
- Bugga Paramesha, .et al. , Antioxidants (Basel), 2021, Feb 24;10(3):338 PMID: 33668369
- Wenhui Yao, .et al. , J Cell Physiol, 2020, 07 August PMID: 32770555
- Guang Bai, .et al. , Epigenetics of Chronic Pain, 2019, Pages 1-48
- Yoshikawa A, .et al. , J Neurochem, 2015, Feb;132(3):342-53 PMID: 25351847
- Nicotinamide riboside chloride is a crystal form of Nicotinamide riboside (NR) chloride. Nicotinamide riboside chloride is used in dietary supplements.
- Shohei Maekawa, .et al. , Neurosci Lett, 2024, Jan 31:821:137623 PMID: 38184017
-
Selective SIRT2 inhibitor
SirReal2 is a potent and selective Sirt2 inhibitor with IC50 of 140 nM.- Yang Li, .et al. , Neoplasia, 2018, Jul; 20(7): 745-756 PMID: 29925042
-
SIRT1/SIRT3 inhibitor
4'-bromo-Resveratrol is a potent inhibitor of the deacetylases sirtuin 1 (SIRT1) and 3 (SIRT3).
-
SIRT2 Inhibitor
SIRT2-IN-8 is a selective inhibitor of SIRT2 (Sirtuin 2), a member of the sirtuin family of proteins implicated in various cellular processes. This compound exhibits strong inhibition of SIRT2 activity, making it a valuable tool for investigating the role of SIRT2 in neurodegenerative diseases, particularly Huntington's and Parkinson's diseases. Its use in research can contribute to a better understanding of the molecular mechanisms underlying these conditions and aid in the development of therapeutic strategies. -
SIRT Inhibitor
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity. -
Sirtuin Inhibitor
Sirt1/2-IN-2 is a dual inhibitor targeting SIRT1 and SIRT2, exhibiting IC50 values of 1.8 μM and 2.4 μM, respectively. This compound effectively prevents the deacetylation of p53 while promoting acetylation of p53 and α-tubulin. Sirt1/2-IN-2 demonstrates pro-apoptotic properties and exhibits anti-proliferative effects on human leukemia cell lines, making it a valuable tool in cancer research and therapeutic studies targeting the sirtuin family. -
Sirtuin Inhibitor
Sirt1/2-IN-3 is a dual inhibitor of the sirtuin family, specifically targeting SIRT1 and SIRT2 with IC50 values of 1.4 μM and 2.0 μM, respectively. This compound effectively prevents the deacetylation of p53, leading to increased acetylation of both p53 and α-tubulin. Sirt1/2-IN-3 has been demonstrated to induce apoptosis and exhibit anti-proliferative effects on human leukemia cell lines, making it a valuable tool for cancer research and the study of cellular aging mechanisms. -
SIRT Inhibitor
SIRT-IN-7 is a selective inhibitor targeting the SIRT family of proteins, specifically SIRT1, SIRT2, and SIRT3. This compound enhances the acetylation and activation of the tumor suppressor protein p53, leading to the inhibition of proliferation and the induction of apoptosis and autophagy in breast cancer cells. SIRT-IN-7 demonstrates significant anti-tumor activity, making it a valuable tool for research in cancer biology and therapeutic development. -
SIRT7 Inhibitor
SIRT7 Inhibitor 97491 is a selective inhibitor of the SIRT7 enzyme, exhibiting an IC50 of 325 nM and effectively reducing its deacetylase activity in a dose-dependent manner. This compound enhances tumor suppression by stabilizing the p53 protein through acetylation at lysine residues K373 and K382. Additionally, SIRT7 Inhibitor 97491 promotes apoptosis via the caspase signaling pathway, making it a valuable tool for cancer research and studies focused on elucidating the role of SIRT7 in tumor progression. -
SIRT6 Inhibitor
SIRT6-IN-3 is a selective inhibitor of SIRT6, exhibiting an IC50 of 7.49 μM. This compound effectively inhibits the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and promotes apoptosis. Additionally, SIRT6-IN-3 enhances the sensitivity of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, making it a valuable tool in pancreatic cancer research. -
HDAC/Sirt2 Inhibitor
Mz325 is a dual inhibitor of histone deacetylases (HDAC) and Sirtuin 2 (Sirt2), with an IC50 of 9.7 μM for Sirt2. By modulating deacetylation processes, Mz325 exhibits bioactivity that can influence cellular pathways involved in cancer progression and neurodegenerative diseases. This compound is useful for research focused on the role of epigenetic regulation in these pathologies. -
SIRT6 PROTAC Degrader
SZU-B6 is a SIRT6-protein-targeting chimeric degrader that achieves a DC50 of 45 nM and 154 nM in SK-HEP-1 and Huh-7 cell lines, respectively. It effectively inhibits the proliferation of SK-HEP-1 cells with an IC50 of 1.51 μM and suppresses colony formation in both SK-HEP-1 and Huh-7 cells. Additionally, SZU-B6 induces apoptosis and causes a cell cycle arrest in the G2/M phase in SK-HEP-1 cells, demonstrating notable antitumor efficacy in mouse models. This compound serves as a valuable tool for studying the functional roles of SIRT6 in cancer research. -
SIRT1 Inhibitor
JGB1741 is a potent and selective inhibitor of SIRT1, exhibiting an IC50 of approximately 15 μM. It displays weak inhibitory effects on SIRT2 and SIRT3, with IC50 values greater than 100 μM. JGB1741 enhances the levels of acetylated p53, promoting p53-mediated apoptosis through modulation of the Bax/Bcl2 ratio, cytochrome c release, and PARP cleavage. This compound is valuable for research applications focusing on breast cancer. -
SIRT1 Activator
BML-278 is a potent SIRT1 activator with an effective concentration (EC150) of 1 μM. It enhances histone modifications by increasing H3K9 methylation and inhibiting H3K9 acetylation, which contributes to improved early embryonic development. Additionally, BML-278 induces G1/S phase cell cycle arrest and reduces senescence in primary human mesenchymal cells. In U937 cells, this compound reduces tubulin acetylation while promoting increased mitochondrial density in murine C2C12 myoblasts, highlighting its versatility in cellular and developmental research applications. -
SIRT6 Inhibitor
SIRT6-IN-6 is a selective inhibitor of SIRT6, demonstrating a potent IC50 of 4.93 μM and a Ki of approximately 10 μM. This compound shows significant selectivity against other histone deacetylases, including SIRT1-3 and HDAC1-11. Research findings indicate that SIRT6-IN-6 effectively elevates the expression of the glucose transporter GLUT-1, which contributes to the reduction of blood glucose levels in mouse models of type 2 diabetes. This reagent is valuable for studies focused on the mechanistic pathways associated with type 2 diabetes and metabolic regulation. -
Sirtuin Inhibitor
MC3482 is a selective inhibitor of sirtuin 5 (SIRT5), known for its role in mitochondrial metabolism and deacylation processes. This compound effectively modulates SIRT5 activity, making it valuable for studies examining the implications of SIRT5 in cellular energy regulation and metabolic disorders. Its use in research can contribute to understanding SIRT5's role in various physiological and pathological conditions, including cancer and neurodegeneration. -
SIRT5 Inhibitor
MC3138 is a selective SIRT5 inhibitor, demonstrating notable antitumor activity in human pancreatic ductal adenocarcinoma (PDAC) cells, with IC50 values ranging from 25.4 to 236.9 μM. In preclinical studies, MC3138 enhances the efficacy of Gemcitabine, significantly inhibiting tumor growth in murine models. This compound is valuable for research into targeted cancer therapies and the modulation of metabolic pathways related to SIRT5 activity. -
SIRT3 Activator
2-APQC is a selective activator of Sirtuin-3 (SIRT3), exhibiting an affinity of Kd=2.756 μM. This compound enhances mitochondrial proline metabolism through the SIRT3-PYCR1 axis and mitigates ROS-induced cytotoxicity by inhibiting the mTOR-p70S6K, JNK, and TGF-β/Smad3 signaling pathways. Additionally, 2-APQC activates the AMPK-Parkin axis, providing a protective effect against myocardial hypertrophy and fibrosis, making it a valuable tool for researching heart failure and related cardiac dysfunctions. -
Sirtuin Activator
ADTL-SA1215 is a novel small-molecule activator of SIRT3, targeting the regulation of autophagy pathways. This compound has demonstrated potential in inducing autophagy in triple-negative breast cancer cells, presenting opportunities for cancer research and therapeutic development. Its specificity for SIRT3 makes it an essential tool for studying the role of sirtuins in cellular metabolism and cancer progression. -
SIRT5 Inhibitor
Et-29 is a potent inhibitor of SIRT5, with a reported Ki value of 40 nM, demonstrating selectivity for this target. By modulating the activity of SIRT5, Et-29 plays a significant role in the study of metabolic processes and post-translational modifications. This reagent is ideal for research applications focused on the regulation of cellular metabolism and potential therapeutic strategies in metabolic diseases. -
SIRT6 Inhibitor
SIRT6-IN-2 is a selective and competitive inhibitor of SIRT6, exhibiting an IC50 of 34 μM. This compound enhances the acetylation of H3K9 and promotes glucose uptake in cultured cells. Additionally, SIRT6-IN-2 demonstrates the ability to reduce T cell proliferation, showcasing its immunosuppressive properties and potential chemosensitizing effects. Research applications include the study of metabolic regulation and immune response modulation. -
SIRT Inhibitor
SIRT-IN-3 is a selective inhibitor of SIRT1 with an IC50 of 17 μM. It demonstrates approximately 4-fold selectivity over SIRT2 and 14-fold selectivity over SIRT3, exhibiting IC50 values of 74 μM and 235 μM, respectively, for these isoforms. This compound is valuable for research applications investigating the role of SIRT1 in cellular processes, including aging, metabolism, and gene regulation. -
SIRT5 Inhibitor
SIRT5 Inhibitor 3 is a potent and competitive inhibitor of SIRT5, exhibiting an IC50 value of 5.9 μM. This compound effectively inhibits the desuccinylation activity of SIRT5, making it a valuable tool for studying the enzyme's role in various biological processes. SIRT5 Inhibitor 3 is applicable in research focused on cancer and neurodegenerative diseases, providing insights into potential therapeutic strategies. -
SIRT3 Activator
SIRT3 Activator 2 is a selective activator of the SIRT3 enzyme. This compound enhances the thermal stability of SIRT3 in SH-SY5Y cells through direct binding, facilitating the clearance of α-synuclein in a SIRT3-dependent manner. In vivo studies demonstrate that SIRT3 Activator 2 improves motor function in Parkinson’s disease models and prevents the loss of dopamine neurons in the substantia nigra in a dose-dependent fashion, making it a valuable tool for research into neurodegenerative disorders. -
Sirt1 Activator
Lumbokinase is a Sirt1 activator that plays a crucial role in mitigating myocardial ischemia-reperfusion (I-R) injury. By enhancing Sirt1 signaling, it promotes autophagic flux while simultaneously reducing oxidative damage, inflammation, and apoptosis associated with I-R events. This compound is valuable for research applications focused on cardiac protection, autophagy modulation, and the underlying mechanisms of ischemic injury. -
Sirtuin Modulator
Sirtuin Modulator 1 is a selective modulator of SIRT1, a member of the sirtuin family of NAD+-dependent deacetylases. With an effective concentration of less than 1 μM, it demonstrates significant biological activity in the regulation of cellular aging and metabolism. This reagent holds potential for research applications in studying age-related diseases, metabolic disorders, and the mechanisms of epigenetic regulation mediated by sirtuins. -
SIRT1 Inhibitor
SIRT1-IN-4 is a selective SIRT1 inhibitor that demonstrates an IC50 of 10.04 μM. This compound is utilized in research focused on cancer biology, providing valuable insights into the role of SIRT1 in tumorigenesis and potential therapeutic approaches. Further studies may explore its utility in modulating cellular processes regulated by SIRT1. -
SIRT1 Activator
E1231 is a potent activator of Sirtuin 1 (SIRT1), exhibiting an EC50 of 0.83 μM. This compound enhances cholesterol and lipid metabolism by interacting with SIRT1 (KD = 9.61 μM) and promoting the deacetylation of liver X receptor-alpha (LXRα), which subsequently increases the expression of ATP-binding cassette transporter A1 (ABCA1). Additionally, E1231 has demonstrated efficacy in reducing atherosclerotic plaque development in ApoE-/- mouse models, making it a valuable tool for research into lipid disorders and related diseases. -
SIRT1 Inhibitor
(S)-Selisistat is a selective inhibitor of SIRT1, demonstrating an IC50 value of 98 nM. This compound effectively modulates the activity of the sirtuin family of proteins, which are implicated in various cellular processes, including metabolism and aging. (S)-Selisistat is valuable for research exploring the role of SIRT1 in age-related diseases and metabolic disorders, making it a crucial tool for investigating therapeutic strategies in these areas. -
SIRT3 Inhibitor
SIRT3-IN-1 is a potent Sirtuin 3 (SIRT3) inhibitor with an IC50 value of 0.043 μM. This compound selectively inhibits SIRT3, making it a valuable tool for studying the role of SIRT3 in acute myeloid leukemia (AML) and other related conditions. Its specific action on SIRT3 allows for targeted investigations into cellular metabolism, oxidative stress response, and potential therapeutic strategies in AML research. -
SIRT7 Inhibitor
YZL-51N is a selective inhibitor of SIRT7, with an IC50 value of 12.71 μM. By occupying the NAD+ binding pocket, YZL-51N inhibits SIRT7 enzyme activity, thereby compromising DNA damage repair mechanisms and reducing cancer cell viability. Its demonstrated anti-tumor activity makes YZL-51N a valuable tool for cancer research applications. -
SIRT1 Inhibitor
SIRT1-IN-3 is a selective inhibitor of SIRT1, exhibiting an IC50 value of 4.2 μM. This compound effectively modulates SIRT1 activity, making it a valuable tool for studies investigating the role of SIRT1 in various biological processes. Research applications include the exploration of SIRT1's involvement in metabolism, aging, and stress response pathways. -
Sirtuin
(R)-Selisistat (R)-EX-527 is a selective inhibitor of SIRT1, exhibiting an IC50 of 98 nM. This compound primarily targets the Sirtuin family of proteins, known to play critical roles in cellular regulation, metabolism, and aging. Research applications include the investigation of SIRT1's involvement in neurodegenerative diseases, metabolic disorders, and cancer biology. (R)-Selisistat serves as a valuable tool for studying the modulation of SIRT1 activity in various biological contexts. -
SIRT1 Inhibitor
SIRT1-IN-2 is a potent and selective inhibitor of SIRT1 (silent information regulator 1), demonstrating an IC50 value of 1.6 μM. This compound plays a critical role in research focused on understanding the regulation of cellular metabolism, aging, and stress response pathways. Its specific inhibition of SIRT1 makes it a valuable tool for studying related biological processes and therapeutic interventions. -
Sirt2 Inhibitor
Sirt2-IN-2 is a selective inhibitor of the Sirtuin 2 (Sirt2) enzyme, exhibiting an IC50 of 0.118 μM. This compound is instrumental in research aimed at studying the role of Sirt2 in cellular processes and its implications in neurodegenerative diseases. Its use facilitates investigations into the potential therapeutic effects of Sirt2 modulation. -
Sirtuin Modulator
Sirtuin modulator 6 is a selective modulator of sirtuin proteins, known for its role in enhancing cellular longevity. This compound exhibits potential therapeutic effects in the context of metabolic disorders such as diabetes and obesity, as well as neurodegenerative and cardiovascular diseases. Its mechanism of action supports research into the modulation of sirtuin pathways, providing insights into various age-related health conditions. -
Sirtuin Modulator
Sirtuin modulator 8 is an effective activator of sirtuin proteins, demonstrating the capacity to enhance sirtuin activity. This compound significantly reduces the expression of monocyte chemoattractant protein-1 (MCP-1) while increasing fibroblast growth factor 21 (FGF21) levels. By regulating genes associated with inflammation and metabolism, Sirtuin modulator 8 is a valuable tool for researching metabolic disorders such as diabetes and obesity, as well as inflammatory diseases. -
Sirt2 inhibitor
SirReal-1 is a selective inhibitor of SIRT2, with an IC50 of 3.7 μM. This compound is utilized in research to investigate the biological role of SIRT2 in various cellular processes and its potential implications in cancer and neurodegenerative diseases. SirReal-1 serves as a valuable tool for elucidating the mechanisms of SIRT2-related signaling pathways. -
Sirtuin Inhibitor
Sirtuin-1 Inhibitor 1 is a selective inhibitor of Sirtuin-1, a key regulator in metabolic processes and cellular aging. This compound demonstrates potential in the study of obesity-related diabetes and age-associated diseases by modulating the activity of Sirtuin-1. Its application in research can enhance understanding of metabolic disorders and the molecular underpinnings of aging. -
SIRT1 Activator
YK-3-237 is a selective activator of SIRT1, targeting mutant p53 proteins. This compound has demonstrated the ability to inhibit the proliferation of triple-negative breast cancer cells, making it a valuable tool for research into cancer biology and potential therapeutic strategies. It may provide insights into the role of SIRT1 in tumor progression and cellular metabolism. -
SirT1 Enhancer
DDL-218 is a potent enhancer of the SirT1 protein, specifically targeting its activity. It has demonstrated efficacy in augmenting SirT1 function in ApoE4-expressing neurons and in murine models of Alzheimer's disease. DDL-218 serves as a valuable tool for investigating SirT1-related pathways and their implications in neurodegenerative disorders, particularly Alzheimer's disease. -
SIRT2 Inhibitor
SIRT2-IN-11 is a selective inhibitor of the SIRT2 enzyme, exhibiting an IC50 value of 18.5 μM. This compound induces apoptosis in a p53-dependent manner, leading to the upregulation of CDKN1A, PUMA, and NOXA, along with increased p53 acetylation. SIRT2-IN-11 is a valuable tool for investigating p53-related cancer mechanisms and therapeutic strategies. -
SIRT2 Inhibitor
AC-93253 is a potent and selective inhibitor of SIRT2, achieving an IC50 value of 6 μM. This compound is instrumental in investigating the role of SIRT2 in tumor biology and may aid in the development of therapeutic strategies targeting SIRT2-related pathways in cancer research. Its specificity enhances the potential for targeted studies in cellular and molecular biology. -
SIRT2 Inhibitor
MIND4-19 is a selective inhibitor of SIRT2, demonstrating an IC50 value of 7.0 μM. This compound is primarily utilized in research related to Huntington's disease, offering insights into the therapeutic potential of SIRT2 modulation in neurodegenerative disorders. Its potency and target specificity make MIND4-19 a valuable tool for studying the role of SIRT2 in disease mechanisms and potential treatments.
